1 ottobre 2020 – The Marketing Authorisation for Global Health Products (MAGHP) aims to make Swissmedic’s authorisation procedure accessible to regulatory authorities in low and middle-income countries. While the new MAGHP Light procedure was originally initiated in response to the COVID-19 pandemic with the aim of accelerating review processes and global access to life-saving medicines to treat COVID-19, the medical application shall now be extended to all medicines.

For further information, see here.